

prejudice or disclaimer from parent application Serial No. 08/258,283. Specific support for the amended claims presented above is discussed below.

The amendments to claim 17 are supported in the specification as follows:

Amendments to claim 17	Support in the Specification
specifically binds to an extracellular domain of the human type beta platelet-derived growth factor receptor (β -PDGF-R) wherein specific binding of the polypeptide or fragment to the human β -PDGF-R has the following effects: i) inhibition of PDGF BB or AB binding to the β -PDGF-R;	Page 38, lines 1-9 and original claim 1.
ii) inhibition of the PDGF-induced β -PDGF-R phosphorylation;	Page 38, line 34 to page 39, line 6 and original claim 1.
iii) inhibition of PDGF-induced dimerization of β -PDGF-R;	Page 39, lines 7-16 and original claim 1.
iv) inhibition of PDGF-induced mitogenesis of cells displaying the human β -PDGF-R; and	Page 39, lines 17-26 and original claim 1.
v) inhibition of PDGF-induced chemotaxis and migration of cells displaying β -PDGF-R	Original claim 1.
said dose being therapeutically effective to at least partially arrest the cellular proliferation, migration or chemotaxis and their symptoms or complications.	Page 27, lines 8-12 and the Abstract.

Written support for new claims 19-21 can be found in the specification as follows.

Claim	Support in Specification
Claim 19	Same as canceled claim 103 in parent application Serial No. 08/258,283. Support can be found at page 6, lines 16-33.
Claim 20	Same as canceled claim 104 in parent application Serial No. 08/258,283. Support can be found at page 6, lines 17-20.
Claim 21	Page 7, lines 25-30 and page 12, lines 1-4.

Claims 22-37 have been copied substantially from claims 1-19 of U.S. Patent 5,620,687 to Hart *et al.* (hereinafter the “‘687 Patent”), and which, as issued on April 15, 1997, was assigned to ZymoGenetics, Inc. These claims are being presented within one year from the issue date of the ‘687 Patent as required under 35 U.S.C. § 135(b). Written support for new claims 22-37 can be found in Applicants’ specification as follows below. Claim 21 would appear to be an appropriate count were an interference to be declared between the present application and the ‘687 Patent, and at least claim 1 of the ‘687 Patent would appear to correspond to such a count.

Claim	Support in Specification
Claim 22	Page 4, lines 19-33; page 6, lines 13-33; page 12, lines 1-4 and page 26, line 34 to page 27, line 31.
Claim 23	<p>The specification describes inhibiting proliferation of smooth muscle cells (page 7, lines 24-30 and page 39, lines 17-26 [human foreskin fibroblasts and primary smooth muscle cells from baboon artery]).</p> <p>The specification describes the inhibition of smooth muscle migration (page 4, line 33 to page 5, line 2; page 6, lines 1-16; and page 12, lines 1-4).</p>
Claim 24	Page 38, lines 1-19; and original claim 1.
Claim 25	Page 16, lines 28-29; Example 1 (beginning at page 30) and original claim 2.
Claim 26	Page 6, lines 15-26; and page 27, line 22 to page 28, line 5.
Claim 27	Page 6, lines 17-20.
Claim 28	Page 6, lines 13-26 and page 27, line 22 to page 38, line 5.
Claim 29	Page 6, lines 17-20.
Claim 30	Page 6, lines 27-29; and page 27, line 32 to page 28, line 5.
Claim 31	Page 6, lines 27-29; and page 27, line 32 to page 28, line 5.
Claim 32	Original claim 17.
Claim 33	Page 17, line 7 to page 18, line 22.
Claim 34	Page 19, lines 29-30.
Claim 35	Page 17, lines 7-31.
Claim 36	Page 17, lines 12-15 and page 25, lines 13-31.
Claim 37	Page 25, lines 13-31.

Written support for new claim 38 is provided as discussed above for claims 17, 21 and 22, and is further found in Applicants' specification as follows:

Claim	Support in Specification
Claim 38	The production and characterization of MAb 2A1E2 is supported in Example 1, for instance, at page 37, line 30; and in original claim 3.

CONCLUSIONS

For the reasons set forth above, entry of the foregoing amendment and examination of the amended claims respectfully is requested. If there are any other filing or claim fees due in connection with the filing of this preliminary amendment, please charge the fees to our Deposit Account No. 50-0310. If a fee is required for any extension of time under 37 C.F.R. § 1.136 not accounted for above, such an extension is requested and the fee should also be charged to our

Deposit Account. The Examiner is invited to telephone either of the undersigned if a discussion might expedite placing the claims in condition for allowance.

Respectfully submitted,


MORGAN, LEWIS & BOCKIUS LLP

Date: April 15, 1998

By: 

Reid G. Adler

Reg. No. 30,988


for Michael S. Tuscan
Reg. No. P43,210

MORGAN, LEWIS & BOCKIUS LLP

1800 M Street, N.W.

Washington, DC 20036

(202) 467-7000